Description
Rising levels of resistance amongst the major respiratory pathogens have compromised empiric antimicrobial therapy. This, coupled with a recent lack in availability of novel classes of antibacterials, has led to a need for new approaches to combat community respiratory tract infections. Bacteriological and clinical efficacy in two trials involving patients with acute bacterial sinusitis and six trials of patients with community-acquired pneumonia has shown that the development of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate (Augmentin SR, available as Augmentin XR in the USA) has allowed amoxicillin/clavulanate to retain its place in the treatment of respiratory tract infections today.
Subject
Adult; Amoxicillin-Potassium Clavulanate Combination/*administration & dosage/pharmacokinetics/therapeutic use; Anti-Bacterial Agents/*administration & dosage/pharmacokinetics/therapeutic use; Bacteria/*drug effects/isolation & purification; Community-Acquired Infections/*drug therapy/microbiology; Humans; Pneumonia/drug therapy/microbiology; Respiratory Tract Infections/*drug therapy/microbiology; Sinusitis/drug therapy/microbiology